Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model

Journal of Pharmaceutical Sciences

Volumn 95, Issue 1, 2006, Pages 116-125

  Carino, Stephen R ^a,b   Sperry, David C ^a   Hawley, Michael ^a  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Bioavailability; Carbamazepine; Dissolution; In vitro models; Polymorphs; Preformulation; Solid forms; Solid state; Solubility; Thermodynamics

Indexed keywords

CARBAMAZEPINE;

APPARATUS; ARTICLE; ARTIFICIAL ORGAN; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DIET RESTRICTION; DOG; DRUG BIOAVAILABILITY; DRUG FORMULATION; DUODENUM; IN VITRO STUDY; INTESTINE TRANSIT TIME; SIMULATION; STOMACH ABSORPTION; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMISTRY; CRYSTALLIZATION; METABOLISM; SOLUBILITY; STOMACH;

ANIMALS; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CRYSTALLIZATION; DOGS; DUODENUM; FASTING; MODELS, BIOLOGICAL; SOLUBILITY; STOMACH;

EID: 33645234034     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20495     Document Type: Article

References (18)

1. Sperry DC, Hawley M. 2000. Dynamic artificial stomach and intestine model to evaluate the bioavailability of drugs and formulations. Abstracts of Papers-American Chemical Society 220th: ANYL-019.
2. Krahn FU, Mielck JB. 1987. Relations between several polymorphic forms and the dihydrate of carbamazepine. Pharm Acta Helv 62:247-254.
3. Behme RJ, Brooke D. 1991. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. J Pharm Sci 80:986-990.
4. Kaneniwa N, Yamaguchi T, Watari N, Otsuka M. 1984. Hygroscopicity of carbamazepine crystalline powders. Yakugaku Zasshi 104:184-190.
5. Lowes MMJ, Caira MR, Letter AP, Van der Watt JG. 1987. Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine. J Pharm Sci 76:744-752.
6. Sethia S, Squillante E. 2002. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J Pharm Sci 91:1948-1957.
7. McMahon LE, Timmins P, Williams AC, York P. 1996. Characterization of dihydrates prepared from carbamazepine polymorphs. J Pharm Sci 85:1064-1069.
8. Rustichelli C, Gamberini G, Ferioli V, Gamberini MC, Ficarra R, Tommasini S. 2000. Solid-state study of polymorphic drugs: Carbamazepine. J Pharm Biomed Anal 23:41-54.
9. Bertilsson L. 1978. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 3:128-143.
10. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP. 1992. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 9:1612-1616.
11. Meyer MC, Straughn AB, Mhatre RM, Shah VP, Williams RL, Lesko LJ. 1998. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 15:1787-1791.
12. Kobayashi Y, Ito S, Itai S, Yamamoto K. 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm 193:137-146.
13. Gupta PK, Robinson JR. 1988. Gastric emptying of liquids in the fasted dog. Int J Pharm 43:45-52.
14. Carriere F, Laugier R, Barrowman JA, Douchet I, Priymenko N, Verger R. Gastric and pancreatic lipase levels during a test meal in dogs. Scand J Gastroenterol 28:443-454.
15. Ceolin R, Toscani S, Gardette M-F, Agafonov VN, Dzyabchenko AV, Bachet B. 1997. X-ray characterization of the triclinic polymorph of carbamazepine. J Pharm Sci 86:1062-1065.
16. Dressman JB. 1986. Comparison of canine and human gastrointestinal physiology. Pharm Res 3:123-131.
17. Kimura T, Higaki K. 2002. Gastrointestinal transit and drug absorption. Biol Pharm Bull 25:149-164.
18. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.